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Background
Peptide YY (PYY) and neuropeptide Y (NPY) are members
of the PP-fold peptide family. PYY is expressed by endo-
crine cells of the gut, whereas NPY occurs in enteric, sen-
sory, cerebral and autonomic neurons. While PYY is
involved in the regulation of gut function and satiety, NPY
is known to contribute to the regulation of emotional-
affective behaviour, cognition, seizure activity, pain and
satiety. Since we have previously found that the NPY sys-
tem plays a role in the gut-brain axis, we explored in
which way knockout of PYY and PYY plus NPY alters the
emotional-affective behaviour in mice and how this phe-
notype is altered by experimental colitis.
Methods
Male wildtype (WT), PYY (PYY-/-) and PYY plus NPY
(PYY+NPY-/-) knockout mice, all with a mixed C57BL/
6:129/SvJ (1:1) background, were used. Mild colitis was
induced by adding dextran sulphate sodium (DSS, 2%) to
the drinking water for 7 days. Inflammation was assessed
by the colonic myeloperoxidase content, anxiety-related
behaviour was evaluated with the elevated plus maze
(EPM) and open field (OF) tests, and depression-like
behaviour was estimated with the forced swim test (FST).
Results
When the animals were phenotyped in the absence of col-
itis, anxiety-like behaviour in the EPM (reduction of open
arm time) was increased in both PYY-/- and PYY+NPY-/-
mice, whereas locomotion remained unaltered. The
results obtained in the OF test were largely similar. The
depression-like behaviour (immobility) in the FST was
markedly enhanced in both PYY-/- and PYY+NPY-/- mice.
DSS-induced colitis was associated with an increase in the
colonic myeloperoxidase content. On the behavioural
level, colitis had genotype-dependent effects on emo-
tional-affective behaviour. Most conspicuous was that col-
itis increased anxiety primarily in WT mice so that in the
EPM test WT mice spent less time on the open arms than
the knockout animals. Similar changes were observed in
the OF test. In contrast, colitis did not alter depression-
like behaviour in WT and PYY+NPY-/- mice but reduced
immobility in PYY-/- mice.
Conclusion
These data show for the first time that the gut hormone
PYY has a significant impact on emotional-affective
behaviour, because its deletion enhances anxiety- and
depression-related behaviour. Colitis enforces anxiety-
like behaviour only in the presence of PYY, whereas in the
absence of PYY depression is less pronounced in animals
with colitis. These data attest to an important role of PYY
in the gut-mood axis.
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